Bayer wants to strengthen his young genetic and cell therapy business with an American expert in genetic modification. The Pharmaceutical and Agrochemical Institute in Berlin announced on Monday that treatments for liver diseases would initially be developed with the help of Mammoth Biosciences’ genetic scissor technology. Overall, Bayer hopes to use technology to quickly develop treatment options.
As part of the collaboration, Mammootty will receive $ 40 million (35 35 million) in the first phase, which could add up to more than $ 1 billion in the future, depending on the achievement of the goals. Related milestones were agreed, it said. In addition, there will be a share of research payments and revenue.
“Amateur coffee fan. Travel guru. Subtly charming zombie maven. Incurable reader. Web fanatic.”
More Stories
Nicolas Loufrani: Young Londoners Design Afro Hair Emojis
US Election: Trump Vs. Harris – 2024 poll numbers in America
Börse Express – USA: Retail sales rise unexpectedly